logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Endometriosis

    Medications for Endometriosis

    FiltersReset Filters
    6 results

    • depo-subq provera

      (medroxyprogesterone acetate)
      Pharmacia & Upjohn Company LLC
      Usage: Depo-subQ Provera 104 is indicated for the prevention of pregnancy and the management of endometriosis-associated pain in females of reproductive age. Long-term use beyond 2 years is not recommended unless other options are inadequate.

    • lupron depot

      (leuprolide acetate)
      AbbVie Inc.
      Usage: LUPRON DEPOT 11.25 mg is indicated for managing endometriosis, including pain relief and lesion reduction, as well as for preoperative anemia improvement in women with uterine leiomyomata (fibroids), used with iron therapy. It is not meant for prolonged use or specific combinations beyond stated limits.

    • myfembree

      (relugolix, estradiol hemihydrate, and norethindrone acetate)
      Sumitomo Pharma America, Inc
      Usage: MYFEMBREE is indicated for managing heavy menstrual bleeding due to uterine leiomyomas and for moderate to severe pain associated with endometriosis in premenopausal women. Its use should be limited to 24 months to mitigate the risk of irreversible bone loss.

    • norethindrone acetate

      (Norethindrone Acetate)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Norethindrone acetate is indicated for treating secondary amenorrhea, endometriosis, and abnormal uterine bleeding caused by hormonal imbalances, excluding cases due to organic issues like fibroids or cancer. It is not approved for use with estrogen therapy in postmenopausal women for endometrial protection.

    • orilissa

      (Elagolix)
      AbbVie Inc.
      Usage: ORILISSA is indicated for managing moderate to severe pain related to endometriosis. Use duration should be limited based on dosage and the patient's coexisting conditions.

    • synarel

      (nafarelin acetate)
      Pfizer Laboratories Div Pfizer Inc
      Usage: SYNAREL is indicated for managing endometriosis in women aged 18 and older, providing pain relief and reducing endometriotic lesions. Treatment duration is limited to 6 months.